drugset / Trial / NCT01496443
TAK-875 Glimepiride Drug-Interaction Study
NaSingle-groupSingle-blind
Summary
The purpose of this study is to determine the pharmacokinetics and safety of TAK-875, once daily (QD), with and without glimepiride in participants with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2012-01
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasiglifam | Small molecule | 50 mg | Oral |
| Subject | Glimepiride | Small molecule | 2 mg | Oral |
Indications
No indication recorded.